Characterization by serial deletion competition ELISAs of HIV-1 V3 loop epitopes recognized by monoclonal antibodies

Molecular Immunology

Volumn 33, Issue 9, 1996, Pages 737-745

  Seligman, Stephen J ^a,g   Binley, James M ^b,c   Gorny, Miroslaw K ^d   Burton, Dennis R ^b   Zolla Pazner, Susan ^d,e   Sokolowski, Karen A ^f  

^a SUNY Downstate Medical Center   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c AARON DIAMOND AIDS RESEARCH CENTER   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f REPLIGEN CORPORATION   (United States)

^g SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Cyclic; ELISA; Epitope; HIV 1; Linear; Peptide; V3 loop

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 120; MONOCLONAL ANTIBODY; SYNTHETIC PEPTIDE;

ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0030174745     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/0161-5890(96)00044-2     Document Type: Article

References (44)

1. Berzofsky J. A., Epstein S. L. and Berkower I. J. (1989) Antigen-antibody interactions and monoclonal antibodies. In Fundamental Immunology (Edited by Paul W. E.), p. 318. Raven Press, New York.
2. Borrow P., Lewicki H., Hahn B. H., Shaw G. M. and Oldstone M. B. (1994) Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68, 6103-6110.
3. Bou-Habib D. C., Roderiquez G., Oravecz T., Berman P. W., Lusso P. and Norcross M. A. (1994) Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. J. Virol. 68, 6006-6013.
4. Brown J. H., Jaredtzky T. S., Gorga J. C., Stern L. J., Urban R. G., Strominger J. L. and Wiley D. C. (1993) Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 364, 33-39.
5. Burton D. R., Barbas C. F., Persson M. A., Koenig S., Chanock R. M. and Lerner R. A. (1991) A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic sero-positive individuals. Proc. natn. Acad. Sci. U.S.A. 88, 10134-10137.
6. Catasti P., Fontenot J. D., Bradbury E. M. and Gupta G. (1995) Local and global structural properties of the HIV-MN V3 loop. J. biol. Chem. 270, 2224-2232.
7. Chandrasekhar K., Profy A. T. and Dyson H. J. (1991) Solution conformational preferences of immunogenic peptides derived from the principal neutralizing determinant of the HIV-1 envelope glycoprotein gp120. Biochemistry 30, 9187-9194.
8. Chicz R. M., Urban R. G., Gorga J. C., Vignali D. A., Lane W. S. and Strominger J. L. (1993) Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J. exp. Med. 178, 27-47.
9. Christodoulides M., McGuinness B. T., Heckels J. E. (1993) Immunization with synthetic peptides containing epitopes of the class 1 outer-membrane protein of Neisseria meningitidis: production of bactericidal antibodies on immunization with a cyclic peptide. J. gen. Microbiol. 139, 1729-1738.
10. Conley A. J., Conard P., Bondy S., Dolan C. A., Hannah J., Leanza W. J., Marburg S., Rivetna M., Rusiecki V. K., Sugg E. E., (1994) Immunogenicity of synthetic HIV-1 gp120 V3-loop peptide-conjugate immunogens. Vaccine 12, 445-451.
11. Emini E. A., Schleif W. A., Nunberg H., Coonley A. J., Eda Y., Tokiyoshi S., Putney S. D., Matsushita S., Cobb K. E., Jett C. M., Eichberg J. W. and Murthy K. K. (1992) Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 355, 728-730.
12. Friquet B., Chaffotte A. F., Djavadi-Ohaniance L. and Goldberg M. E. (1995) Under proper experimental conditions the solid-phase antigen does not disrupt the liquid phase equilibrium when measuring dissociation constants by competition ELISA. J. immunol. Meth. 182, 145-147.
13. Geysen H. M., Meloen R. H. and Barteling S. J. (1984) Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid. Proc. natn. Acad. Sci. U. S. A. 81, 3998-1002.
14. Geysen H. M., Rodda S. J., Mason T. J., Tribbick G. and Schoofs P. G. (1987) Strategies for epitope analysis using peptide synthesis. J. immunol. Meth. 102, 259-274.
15. Geysen H. M., Mason T. J. and Rodda S. J. (1988) Cognitive features of continuous antigenic determinants. J. molec. Recognit. 1, 32-41.
16. Ghiara J. B., Stura E. A., Stanfield R. L., Profy A. T. and Wilson I. A. (1994) Crystal structure of the principal neutralization site of HIV-1. Science 264, 82-85.
17. Golding H., D'Souza M. P., Bradac J., Mathieson B. and Fast P. (1994) Neutralization of HIV-1. AIDS Res. Hum. Retroviruses 10, 633-643.
18. Gorny M. K., Xu J. Y., Gianakakos V., Karwowska S., Williams C., Sheppard H. W., Hanson C. V. and Zolla-Pazner S. (1991) Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein. Proc. natn. Acad. Sci. U.S.A. 88, 3238-3242.
19. Gorny M. K., Conley A. J., Karwowska S., Buchbinder A., Xu J. Y., Emini E. A., Koenig S. and Zolla-Pazner S. (1992) Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody. J. Virol. 66, 7538-7542.
20. Gorny M. K., Xu J. Y., Karwowska S., Buchbinder A. and Zolla-Pazner S. (1993) Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. J. Immun. 150, 635-643.
21. Goudsmit J., DeBouck C., Meloen R. H., Smit L., Bakker M., Asher D. M., Wolff A. V., Gibbs Jr C. J. and Gajdusek D. C. (1988) Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. Proc. natn. Acad. Sci. U.S.A. 85, 4478-4482.
22. Hanson C. V. (1994) Measuring vaccine-induced HIV neutralization: report of a workshop. AIDS Res. Hum. Retroviruses 10, 645-648.
23. Ivanov V. S., Suvorova Z. K., Tchikin L. D., Kozhich A. T. and Ivanov V. T. (1992) Effective method for synthetic peptide immobilization that increases the sensitivity and specificity of ELISA procedures. J. immunol. Meth. 153, 229-233.
24. Javaherian K., Langlois A. J., McDanal C., Ross K. L., Eckler L. I., Jellis C. L., Profy A. T., Rusche J. R., Bolognesi D. P., Putney S. D. and Matthews T. J. (1989) Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc. natn. Acad. Sci. U.S.A. 86, 6768-6772.
25. Javaherian K., Langlois A. J., LaRosa G. J., Profy A. T., Bolognesi D. P., Herlihy W. C., Putney S. D. and Matthews T. J. (1990) Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1. Science 250, 1590-1593.
26. Jerne N. K. (1960) Immunological speculations. A. Rev. Microbiol. 14, 341-358.
27. Koup R. A., Safrit J. T., Cao Y., Andrews C. A., McLeod G., Borkowsky W., Farthing C. and Ho D. D. (1994) Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol, 68, 4650-4655.
28. Laman J. D., Schellekens M. M., Yusuf H. A., Lewis G. K., Tersmette M., Fouchier R. A. M., Langedijk J. P. M., Claassen E. and Boersma W. J. A. (1992) Variant-specific monoclonal and group-specific polyclonal human immunodeficiency virus type 1 neutralizing antibodies raised with synthetic peptides from the gp120 third variable domain. J. Virol. 66, 1823-1831.
29. Langedijk J. P., Back N. K., Kinney-Thomas E., Bruck C., Francotte M., Goudsmit J. and Meloen R. H. (1992) Comparison and fine mapping of both high and low neutralizing monoclonal antibodies against the principal neutralization domain of HIV-1. Arch. Virol. 126, 129-146.
30. LaRosa G. J., Davide J. P., Weinhold K., Waterbury J. A., Profy A. T., Lewis J. A., Langlois A. J., Dreesman G. R., Boswell R. N., Shadduck P. et al. (1990) Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. Science 249, 932-935.
31. Moore J. P., McCutchan F. E., Poon S. W., Mascola J., Liu J. and Cao Y., Ho D. D. (1994) Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies. J. Virol. 68, 8350-8364.
32. Moore J. P., Cao Y., Qing L., Sattentau Q. J., Pyati J., Koduri R., Robinson J., Barbas C. F., Burton D. R., Ho D. D. (1995a) Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J. Virol. 69, 101-109.
33. Moore J. P., Trkola A., Korber B., Boots L. J., Kessler J. A., McCutchan F. E., Mascola J., Ho D. D., Robinson J. and Conley A. J. (1995b) A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B. J. Virol. 69, 122-130.
34. Rini J. M., Stanfield R. L., Stura E. A., Salinas P. A., Profy A. T. and Wilson I. A. (1993) Crystal structure of a human immunodeficiency virus type 1 neutralizing antibody, 50.1, in complex with its V3 loop peptide antigen. Proc. natn. Acad. Sci. U.S.A. 90, 6325-6329.
35. Sattentau Q. J. and Moore J. P. (1995) Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. J. exp. Med. 182, 185-196.
36. Seligman S. J. (1994a) Influence of solid-phase antigen in competition enzyme-linked immunosorbent assays (ELISAs) on calculated antigen-antibody dissociation constants. J. immunol. Meth. 168, 101-110.
37. Seligman S. J. (1994b) Serial deletion mapping by competition ELISA assay: characterization of a linear epitope in the V3 loop of HIV-1. AIDS Res. Hum. Retroviruses 10, 149-156.
38. Seligman S. J. (1995) Reply to the letter of B. Friquet et al.. J. immunol. Meth. 182, 149-150.
39. Stevens F. J. (1987) Modification of an ELISA-based procedure for affinity determination: Correction necessary for use with bivalent antibody. Molec. Immun. 24, 1055-1060.
40. Sullivan N., Sun Y., Li J., Hofmann W. and Sodroski J. (1995) Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line passaged human immunodeficiency virus type 1 isolates. J. Virol. 69, 4413-4422.
41. VanCott T. C., Bethke F. R., Polonis V. R., Gorny M. K., Zolla-Pazner S., Redfield R. R. and Birx D. L. (1994) Dissociation rate of antibody-gp120 binding interactions is predictive of V3-mediated neutralization of HIV-1. J. Immun. 153, 449-459.
42. Wang C. Y., Looney D. J., Li M. L., Walfield A. M., Ye J., Hosein B., Tam J. P. and Wong-Staal F. (1991) Long-term high titer neutralizing activity induced by octameric synthetic HIV-1 antigen. Science 254, 285-288.
43. White-Scharf M. E., Potts B. J., Smith L. M., Sokolowski K. A., Rusche J. R. and Silver S. (1993) Broadly neutralizing monoclonal antibodies to the V3 region of HIV-1 can be elicited by peptide immunization. Virology 192, 197-206.
44. Zvi A., Kustanovich I., Feigelson D., Levy R., Eisenstein M., Matsushita S., Richalet-Secordel P., Regenmortel M. H. and Anglister J. (1995) NMR mapping of the antigenic determinant recognized by an anti-gp120, human immunodeficiency virus neutralizing antibody. Eur. J. Biochem. 229, 178-187.